Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction
In this trial, Capricor Therapeutics used donor cells derived from the heart to treat patients at risk for developing heart failure after a heart attack. In previous clinical studies, the cells appeared to reduce scar tissue, promote blood vessel growth and improve heart function. This trial is ending after failing to achieve its primary goal of reduction of scar size in the heart.
Randomized, double-blind placebo-controlled. Intra-coronary delivery, single dose.
Primary: Determine whether treatment is safe and causes reduction in cardiac scar size in patients with heart failure after a heart attack. Secondary: Assess for other structural or functional cardiac benefits.
This study is ongoing, but not recruiting participants.